MSB

3.21%

$1.13 mesoblast limited

Countdown to Interim Analysis, page-91

First 91 Last

Share
Profile

Follow
Treed

3,891 Posts.

1320

15/07/20

12:28

Post #: 45879728
Share

Originally posted by bedger: ↑

Its great that you are well informed on Mesoblast, but rather than treat this as a p*ssing contest, why not share with other HC readers your insight?

For those unaware, Mesoblast is partnering with the Cardiothoracic surgical trials networks established by the NIH (National Institues of Health). Presumably thats what bhoulahan means when he says "MSB does not have any data - they are not running the trials"?

"Mesoblast Limited (ASX:MSB; Nasdaq:MESO) today announced that its allogeneic mesenchymal stem cell (MSC) product candidate remestemcel-Lwill be formally evaluated in a randomized, placebo-controlledtrial in 240 patients with acute respiratory distress syndrome (ARDS) caused by coronavirus infection (COVID-19).This multi-centerPhase 2/3 trial will be conducted as a public-privatepartnership in a collaboration with the Cardiothoracic Surgical Trials Network (CTSN), which was established by the United States National Institutes of Health's National Heart, Lung and Blood Institute (NHLBI) as a flexible platform for conducting collaborative trials. Mesoblast holds an Investigational New Drug (IND) Application from the United States Food and Drug Administration (FDA) for use of remestemcel-Lin the treatment of patients with COVID-19ARDS, and will provide investigational product for the trial.Mesoblast Chief Executive Dr Silviu Itescu stated: "This significant public-private partnership is a prime example of how the combined resources of industry and government can be leveraged to evaluate in a most efficient and rigorous manner the potential of innovative therapies to make a meaningful difference to patient outcomes."CTSN Chairman Dr A. Marc Gillinov said: "We are excited to work with Mesoblast to make a real impact on the high mortality associated with COVID-19. This randomized controlled trial is in line with our mandate to rigorously evaluate novel therapies for public health imperatives.""

Mesoblast does have the data and they are running the trials, in a partnership with the CTSN, which adds a great deal of credibility to the study results when they do come out.

Expand

Sorry @bedger but Mesoblast are not running the trials, that is being done by the Icahn School of Medicine. And that adds even more credibility to the study results when they do come out.

From https://clinicaltrials.gov/ct2/show/study/NCT04371393?term=mesoblast&draw=2

MSB Price at posting: $3.47 Sentiment: Buy Disclosure: Held
36 Upvote

0 Great analysis

Reply

Top Stories

The market's shrugged at China's stimulus measures all year. Why is this one different?

NAM

ACCC seeks Olam divestments before it can buy Namoi Cotton

KAL

KalGold rolls out detailed aeromagnetic survey across Pinjin project

ACW

Actinogen Medical ramps up Alzheimer’s treatment trials, targeting fast-track global approvals

DEG

HotCopper users muse on De Grey's denial of Agnico Eagle takeover bid – but who are Agnico?

The winners & losers on market if negative gearing were gone

STK

5.6g/t gold intercept at Serbia's Rogozna supports Strickland's hopes for high-grade core

ESR

Estrella first foreign entity to win tenements in Timor-Leste under new laws ahead of 2025 tenders

COD

Coda Minerals (ASX:COD) enters rights issue to further exploration in South Australia

Week 39 Wrap: What HotCopper’s watching; China’s new stimmy moves boost metals; Oz CPI drop

There are more pages in this discussion • 105 more messages in this thread...

First 91 Last

Add MSB (ASX) to my watchlist

(20min delay)
Last $1.13		Change 0.035(3.21%)		Mkt cap ! $1.284B

Open	High	Low	Value	Volume
$1.09	$1.13	$1.07	$3.910M	3.535M

Buyers (Bids)

No.	Vol.	Price($)
2	27197	$1.11

Sellers (Offers)

Price($)	Vol.	No.
$1.13	43578	3

View Market Depth

No.	Vol.	Price($)
4	31763	1.100
2	33264	1.090
2	18897	1.085
2	18926	1.080
1	18000	1.075

Price($)	Vol.	No.
1.130	23400	3
1.135	1090	1
1.140	65000	4
1.145	64500	3
1.150	92314	9

Last trade - 16.10pm 27/09/2024 (20 minute delay)

MSB (ASX) Chart

Countdown to Interim Analysis, page-91

The market's shrugged at China's stimulus measures all year. Why is this one different?

ACCC seeks Olam divestments before it can buy Namoi Cotton

KalGold rolls out detailed aeromagnetic survey across Pinjin project

Actinogen Medical ramps up Alzheimer’s treatment trials, targeting fast-track global approvals

HotCopper users muse on De Grey's denial of Agnico Eagle takeover bid – but who are Agnico?

The winners & losers on market if negative gearing were gone

5.6g/t gold intercept at Serbia's Rogozna supports Strickland's hopes for high-grade core

Estrella first foreign entity to win tenements in Timor-Leste under new laws ahead of 2025 tenders

Coda Minerals (ASX:COD) enters rights issue to further exploration in South Australia

Week 39 Wrap: What HotCopper’s watching; China’s new stimmy moves boost metals; Oz CPI drop

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

Countdown to Interim Analysis, page-91

Top Stories

The market's shrugged at China's stimulus measures all year. Why is this one different?

ACCC seeks Olam divestments before it can buy Namoi Cotton

KalGold rolls out detailed aeromagnetic survey across Pinjin project

Actinogen Medical ramps up Alzheimer’s treatment trials, targeting fast-track global approvals

HotCopper users muse on De Grey's denial of Agnico Eagle takeover bid – but who are Agnico?

The winners & losers on market if negative gearing were gone

5.6g/t gold intercept at Serbia's Rogozna supports Strickland's hopes for high-grade core

Estrella first foreign entity to win tenements in Timor-Leste under new laws ahead of 2025 tenders

Coda Minerals (ASX:COD) enters rights issue to further exploration in South Australia

Week 39 Wrap: What HotCopper’s watching; China’s new stimmy moves boost metals; Oz CPI drop

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News